rabbit anti phosphorylated jak2  (Cell Signaling Technology Inc)

Journal: International Journal of Molecular Sciences

Article Title: Tedizolid Targets AQP9-JAK/STAT Axis to Suppress Metastatic Progression in Clear Cell Renal Cell Carcinoma: Mechanism and Therapeutic Implications

doi: 10.3390/ijms27104234

Figure Lengend Snippet: AQP9 activates the JAK/STAT signaling pathway in ccRCC cells. ( A ) A KEGG pathway enrichment analysis of genes co-expressed with AQP9. ( B ) A GSEA plot showing significant enrichment of the JAK/STAT signaling pathway gene set in tumors with high AQP9 expression. ( C , D ) A Western blot analysis of key JAK/STAT pathway proteins (JAK2, STAT3, and their phosphorylated forms p-JAK2 and p-STAT3) in Caki-1 and 786-O cells after AQP9 knockdown or overexpression. β-actin served as a loading control. The data are presented as mean ± SD. **** p < 0.0001.

Article Snippet: The samples were resolved by SDS-PAGE, transferred onto PVDF membranes, and then incubated overnight at 4 °C with primary antibodies against AQP9 (sc-74409 G-3, 1:100, Santa Cruz Biotechnology, Dallas, TX, USA)), N-cadherin (A0433, 1:1000, ABclonal, Wuhan, China), E-cadherin (A0433, 1:1000, ABclonal, China), Vimentin (10366-1-AP, 1:20,000, Proteintech, Rosemont, IL, USA), Snail (A5243, 1:1000, ABclonal, China), MMP2 (A19080, 1:1000, ABclonal, China), MMP9 (F0008, 1:1000, Selleck Chemicals, Houston, TX, USA), phosphorylated JAK2 (AP0531, 1:1000, ABclonal, China), JAK2 (K5N8, 1:1000, Selleck, WA, USA), phosphorylated STAT3 (B17F7, 1:2000, Selleck, WA, USA), STAT3 (WL01836, 1:1000, Wanleibio, Shenyang, China), and β-actin (AC038, 1:20,000, ABclonal, China).

Techniques: Expressing, Western Blot, Knockdown, Over Expression, Control

Journal: International Journal of Molecular Sciences

Article Title: Tedizolid Targets AQP9-JAK/STAT Axis to Suppress Metastatic Progression in Clear Cell Renal Cell Carcinoma: Mechanism and Therapeutic Implications

doi: 10.3390/ijms27104234

Figure Lengend Snippet: AQP9 regulates EMT in ccRCC via the JAK/STAT pathway. ( A , C ) A wound healing assay showing that the STAT3 inhibitor Stattic attenuates the enhanced migration of ccRCC cells induced by AQP9 overexpression. ( B , D ) Transwell migration and invasion assays showing that Stattic attenuates the enhanced migration and invasion of ccRCC cells induced by AQP9 overexpression. ( E ) A Western blot analysis showing that Stattic reverses the activation of the JAK2/STAT3 pathway induced by AQP9 overexpression. ( F ) A Western blot analysis showing that Stattic reverses the promotion of EMT markers induced by AQP9 overexpression. The data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The samples were resolved by SDS-PAGE, transferred onto PVDF membranes, and then incubated overnight at 4 °C with primary antibodies against AQP9 (sc-74409 G-3, 1:100, Santa Cruz Biotechnology, Dallas, TX, USA)), N-cadherin (A0433, 1:1000, ABclonal, Wuhan, China), E-cadherin (A0433, 1:1000, ABclonal, China), Vimentin (10366-1-AP, 1:20,000, Proteintech, Rosemont, IL, USA), Snail (A5243, 1:1000, ABclonal, China), MMP2 (A19080, 1:1000, ABclonal, China), MMP9 (F0008, 1:1000, Selleck Chemicals, Houston, TX, USA), phosphorylated JAK2 (AP0531, 1:1000, ABclonal, China), JAK2 (K5N8, 1:1000, Selleck, WA, USA), phosphorylated STAT3 (B17F7, 1:2000, Selleck, WA, USA), STAT3 (WL01836, 1:1000, Wanleibio, Shenyang, China), and β-actin (AC038, 1:20,000, ABclonal, China).

Techniques: Wound Healing Assay, Migration, Over Expression, Western Blot, Activation Assay

Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin inhibits JAK2/STAT3 signaling and restores tight junction proteins in dextran sulfate sodium-induced colitis. (A) Representative western blotting images of p-JAK2, JAK2, p-STAT3, STAT3, IL-6, occludin, ZO-1 and β-actin expression in colon tissues. Densitometric semi-quantification of the relative protein expression levels of (B) p-JAK2/β-actin, (C) JAK2/β-actin, (D) p-JAK2/JAK2, (E) p-STAT3/β-actin, (F) STAT3/β-actin, (G) p-STAT3/STAT3, (H) IL-6/β-actin, (I) occludin/β-actin and (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. control group; # P<0.05 and ## P<0.01 vs. normal group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; C, control group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; IL-6, ZO-1, zona occludens-1.

Article Snippet: The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature, then incubated at 4°C overnight with primary antibodies against IL-6 (1:1,000; cat. no. Bs-0782R; BIOSS), phosphorylated (p-)JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), zona occludens-1 (ZO-1; 1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam).

Techniques: Western Blot, Expressing, Control

Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin suppresses JAK2/STAT3 activation in IL-6-stimulated Caco-2 cells with STAT3 silencing. (A) Western blot analysis of p-JAK2, JAK2, p-STAT3, STAT3, occludin and ZO-1 in Caco-2 cells under indicated treatments. (B) Validation of STAT3 knockdown efficiency: Relative STAT3 expression in cells transfected with siSTAT3 vs. siNC. ## P<0.01 vs. siNC. Densitometric semi-quantification of relative protein expression levels of (C) p-JAK2/β-actin, (D) JAK2/β-actin, (E) p-JAK2/JAK2, (F) p-STAT3/β-actin, (G) STAT3/β-actin, (H) p-STAT3/ STAT3, (I) occludin/β-actin, (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. IL-6 group; ## P<0.01 vs. normal group; Δ P<0.05 and ΔΔ P<0.01 IL-6 + Nar group vs. IL-6 + Nar + siSTAT3 group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; ZO-1, zona occludens-1; si, small interfering RNA; NC, negative control.

Article Snippet: The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature, then incubated at 4°C overnight with primary antibodies against IL-6 (1:1,000; cat. no. Bs-0782R; BIOSS), phosphorylated (p-)JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), zona occludens-1 (ZO-1; 1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam).

Techniques: Activation Assay, Western Blot, Biomarker Discovery, Knockdown, Expressing, Transfection, Small Interfering RNA, Negative Control